An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial

Part of paid clinical trials in Tucson, Arizona.

Sponsor
AbbVie
Study ID
NCT03844048
Phase
PHASE3
Status
Active Not Recruiting

Conditions

Eligibility Criteria

Sex
ALL
Age
N/A - N/A
Healthy Volunteers
Not accepted

Interventions

  • Venetoclax — DRUG
    oral; film-coated tablets or tablets for oral suspension

Study Details

The purpose of this extension study is to provide venetoclax and obtain long-term safety data for subjects who continue to tolerate and derive benefit from receiving venetoclax in ongoing studies.

Key Dates

Start date
Sep 6, 2019
Status verified
May 2026
Primary completion
Aug 31, 2027
Completion
Aug 31, 2027

Study Design

Enrollment
165 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Venetoclax
    Venetoclax at the same dose administered to each subject during the previous study in which they were enrolled.

Primary Outcome Measure

Number of Participants With Adverse Events [ Time Frame: From first dose of study drug until 30 days following last dose of study drug (up to approximately 5 years). ]

Locations (7)

FacilityCityStateZIPSite coordinators
University of Arizona Cancer Center - Tucson /ID# 210548TucsonArizona85724-
UCLA Santa Monica Hematology Oncology /ID# 210551Los AngelesCalifornia90095-
Ingalls Memorial Hosp /ID# 210553HarveyIllinois60426-
Dana-Farber Cancer Institute /ID# 215360BostonMassachusetts02215-
University of Michigan Comprehensive Cancer Center Michigan Medicine /ID# 231132Ann ArborMichigan48109-
Dartmouth-Hitchcock Medical Center /ID# 210555LebanonNew Hampshire03756-
Swedish Medical Center - Seattle /ID# 213120SeattleWashington98104-

Find similar trials in Tucson, AZ

By condition
Leukemia (other)Multiple myeloma
By specialty
OncologyBlood cancer
By research site
University of Arizona Cancer Center - Tucson· Tucson, AZUCLA Santa Monica Hematology Oncology· Los Angeles, CAIngalls Memorial Hosp· Harvey, ILDana-Farber Cancer Institute· Boston, MAUniversity of Michigan Comprehensive Cancer Center Michigan Medicine· Ann Arbor, MIDartmouth-Hitchcock Medical Center· Lebanon, NH

Related Studies